This retrospective study aimed to evaluate the impact of Anti‐Obesity Medication (AOM) initiation, usage and duration on weight loss in a 72‐week precision obesity program. The type of AOM, diet and exercise plan was chosen based upon an individual's biological and psychosocial needs. The 72‐week study duration allowed for a fair investigation of the downstream impact of delayed vs early AOM initiation.
Participants, aged ≥18 years with BMI ≥30 kg/m2, enrolled from March 1, 2015 to April 1, 2017, were included. Subgroups were assigned by AOM usage (users versus non‐users, early (before 8 weeks) versus delayed (after 8 weeks) AOM initiation, and short (<6 months) vs long (≥ 6months) AOM duration. Primary endpoints included change in baseline weight at 72 weeks and proportions achieving ≥5%, ≥10%, and ≥15% weight loss. Outcomes were compared between subgroups.
Mean age and BMI (N=129) were 45.0±14.0 years and 37.0±6.0 kg/m2; 67% were female. At week 72, AOM users (N=71) achieved significantly greater mean percentage reduction in baseline weight than non‐users (N=58). On average, baseline weight decreased by 14.04±6.2% in users versus 10.9±6.8% in non‐users (p=0.008). 84% and 94% of non‐user and AOM users lost > 5% weight loss (P=0.006). A higher proportion of users lost ≥15% of weight (45.1% versus 19.0%; p<0.001). Mean percentage reduction in weight was greater for early versus delayed starters (‐17.60±5.3% versus ‐13.95±5.5%; p=0.024), and longer AOM usage trended toward increased weight loss.
Early initiation of AOM may enhance weight‐loss.